Zentalis Pharmaceuticals (ZNTL) Net Income towards Common Stockholders (2019 - 2026)

Zentalis Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$35.4 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 26.78% year-over-year to -$35.4 million in Q1 2026; TTM through Mar 2026 was -$124.1 million, a 44.63% increase from a year earlier, with the FY2025 full-year figure at -$137.1 million, up 17.37% from the prior year.
• Net Income towards Common Stockholders held at -$35.4 million in Q1 2026 per ZNTL's latest filing, from -$35.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $10.0 million in Q1 2024 and bottomed at -$98.9 million in Q2 2023.
• The 5-year median for Net Income towards Common Stockholders is -$48.3 million (2025), against an average of -$49.1 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 116.47% in 2024 and tumbled 580.87% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$48.2 million in 2022, then decreased by 26.53% to -$60.9 million in 2023, then gained by 22.1% to -$47.5 million in 2024, then rose by 25.82% to -$35.2 million in 2025, then declined by 0.39% to -$35.4 million in 2026.
• Per Business Quant, the three latest ZNTL Net Income towards Common Stockholders figures stand at -$35.4 million (Q1 2026), -$35.2 million (Q4 2025), and -$26.7 million (Q3 2025).